^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Peritoneal Cancer |
| Drug: | iniparib (BSI 201) (PARP1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer
Published date:
01/30/2023
Excerpt:
Eligible patients had a histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, or primary peritoneal carcinoma....Carboplatin (AUC 4 IV day 1), gemcitabine (1000 mg/m2 IV days 1 and 8), and iniparib (5.6 mg/kg IV days 1, 4, 8, and 11) were given on a 21-day cycle….The overall response rate (ORR RECIST 1.0) in platinum sensitive disease was 66% (95% CI, 49-80) with a higher response rate in the 15 pts with germline BRCA mutations (gBRCAmut) (73%).
Secondary therapy:
carboplatin + gemcitabine
DOI:
https://doi.org/10.1093/oncolo/oyac275
Trial ID:
